Galectin-3 and post-myocardial infarction cardiac remodeling
- PMID: 26101067
- DOI: 10.1016/j.ejphar.2015.06.025
Galectin-3 and post-myocardial infarction cardiac remodeling
Abstract
This review summarizes the current literature regarding the involvement and the putative role(s) of galectin-3 in post-myocardial infarction cardiac remodeling. Post-myocardial infarction remodeling is characterized by acute loss of myocardium, which leads to structural and biomechanical changes in order to preserve cardiac function. A hallmark herein is fibrosis formation, both in the early and late phase following acute myocardial infarction. Galectin-3, a β-galactoside-binding lectin, which is a shared factor in fibrosis formation in multiple organs, has an established role in cardiac fibrosis in the setting of pressure overload, neuro-endocrine activation and hypertension, but its role in post- myocardial infarction remodeling has received less attention. However, accumulative experimental studies have shown that myocardial galectin-3 expression is upregulated after myocardial infarction, both on mRNA and protein level. This already occurs shortly after myocardial infarction in the infarcted and border zone area, and also at a later stage in the spared myocardium, contributing to tissue repair and fibrosis. This is associated with typical aspects of fibrosis formation, such as apposition of matricellular proteins and increased factors of collagen turnover. Interestingly, myocardial fibrosis in experimental post-myocardial infarction cardiac remodeling could be attenuated by galectin-3 inhibition. In clinical studies, circulating galectin-3 levels have been shown to identify patients at risk for new-onset heart failure and atrial fibrillation. Circulating galectin-3 levels also predict progressive left ventricular dilatation after myocardial infarction. From literature we conclude that galectin-3 is an active player in cardiac remodeling after myocardial infarction. Future studies should focus on the dynamics of galectin-3 activation after myocardial infarction, and study the possibilities to target galectin-3.
Keywords: Biomarker; Fibrosis; Galectin-3; Heart failure; Myocardial infarction; Remodeling.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
-
Integration of "omics" techniques: Dronedarone affects cardiac remodeling in the infarction border zone.Exp Biol Med (Maywood). 2018 Jul;243(11):895-910. doi: 10.1177/1535370218788517. Exp Biol Med (Maywood). 2018. PMID: 30105952 Free PMC article.
-
Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis.Am J Pathol. 2016 May;186(5):1114-27. doi: 10.1016/j.ajpath.2015.12.017. Epub 2016 Mar 3. Am J Pathol. 2016. PMID: 26948424 Free PMC article.
-
Galectin-3 expression in cardiac remodeling after myocardial infarction.Int J Cardiol. 2014;172(1):e98-e101. doi: 10.1016/j.ijcard.2013.12.129. Epub 2014 Jan 4. Int J Cardiol. 2014. PMID: 24433619 No abstract available.
-
Value of Galectin-3 in Acute Myocardial Infarction.Am J Cardiovasc Drugs. 2020 Aug;20(4):333-342. doi: 10.1007/s40256-019-00387-9. Am J Cardiovasc Drugs. 2020. PMID: 31784887 Review.
-
Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration.Cell Tissue Res. 2016 Sep;365(3):563-81. doi: 10.1007/s00441-016-2431-9. Epub 2016 Jun 21. Cell Tissue Res. 2016. PMID: 27324127 Free PMC article. Review.
Cited by
-
Prognostic Value of Serum Galectin-3 in Chronic Heart Failure: A Meta-Analysis.Front Cardiovasc Med. 2022 Feb 18;9:783707. doi: 10.3389/fcvm.2022.783707. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35252382 Free PMC article.
-
Left ventricular remodeling after the first myocardial infarction in association with LGALS-3 neighbouring variants rs2274273 and rs17128183 and its relative mRNA expression: a prospective study.Mol Biol Rep. 2018 Dec;45(6):2227-2236. doi: 10.1007/s11033-018-4384-4. Epub 2018 Sep 18. Mol Biol Rep. 2018. PMID: 30229476
-
Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72 H in an Experimental Rat Model of Acute Myocardial Infarction.J Cardiovasc Transl Res. 2017 Dec;10(5-6):460-469. doi: 10.1007/s12265-017-9761-1. Epub 2017 Jul 17. J Cardiovasc Transl Res. 2017. PMID: 28718055
-
Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition.Sci Rep. 2019 Jul 3;9(1):9607. doi: 10.1038/s41598-019-46119-6. Sci Rep. 2019. PMID: 31270370 Free PMC article.
-
Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities.Mediators Inflamm. 2018 Nov 5;2018:8696543. doi: 10.1155/2018/8696543. eCollection 2018. Mediators Inflamm. 2018. PMID: 30524200 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical